Pharmacokinetics and Relative Bioavailability of XmAb®5871 Administered Either Intravenously or Subcutaneously
Phase of Trial: Phase I
Latest Information Update: 23 May 2017
At a glance
- Drugs XmAb 5871 (Primary) ; XmAb 5871 (Primary)
- Indications Autoimmune disorders; Rheumatoid arthritis; Systemic lupus erythematosus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Xencor
- 09 May 2017 Results published in a Xencor media release.
- 01 May 2017 Status changed from active, no longer recruiting to completed.
- 28 Feb 2017 According to a Xencor media release, data expected in the first half of 2017.